Search Button
The Company'S First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine
2022-11-21
Acceptance Of The Application For Clinical Trial Of Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
2022-10-27
Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines
2022-08-19
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine
2022-08-10
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
2022-08-03
Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines
2022-06-27
Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV
2022-05-02
Receipt Of Approval From The UAE For Phase II/III Clinical Trial Of Sequential Booster Vaccination For ReCOV
2022-04-13
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022-05-11
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2022-02-12
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques
2021-11-09